How this Gainesville company plans to give doctors new tool in fighting opioid addiction - Gainesville Times

By allowing ads to appear on this site, you support the local businesses who, in turn, support great journalism.

How this Gainesville company plans to give doctors new tool in fighting opioid addiction

Pro-Genex CEO Robbie Rupard, right, and President and CEO Brett Grauss are leading the Gainesville pharmacogenomics company in starting a project that will hypothetically lead to predicting the risk level of opioid addiction with patients. Rupard was inspired by Penn State’s similar study in 2017 with a 37-person sample size. Rupard will increase the sample size to 1,000; therefore, adding more accuracy to the study. - photo by Scott Rogers

07062019 OPIOIDS 3.jpg — Pro-Genex CEO Robbie Rupard, right, and President and CEO Brett Grauss are leading the Gainesville pharmacogenomics company in starting a project that will hypothetically lead to predicting the risk level of opioid addiction with patients. Rupard was inspired by Penn State’s similar study in 2017 with a 37-person sample size. Rupard will increase the sample size to 1,000; therefore, adding more accuracy to the study. - photo by Scott Rogers

One opioid prescription can be all it takes to launch into the downward spiral of addiction.